Testosterone sometimes enters a menopause consultation because of distressing low sexual desire. It should be assessed as a separate clinical question, with attention to other causes and the limitations of the evidence.
In the US there is no FDA-approved testosterone formulation specifically indicated for women. A compounded preparation or off-label prescription therefore needs an explicit explanation of the goal, uncertainty, possible harms and follow-up.
In this entry
Define the concern before ordering a solution
Low desire can be affected by pain, mood, relationships, other medicines, sleep and medical conditions. Fatigue is similarly nonspecific. A testosterone result alone cannot establish the cause of those concerns or predict that adding the hormone will help.
Ask what condition the clinician is treating and what assessment supports it. Evidence for a particular sexual-health indication should not be extended to broad promises about weight loss, energy, cognition or reversing aging.
Clarify the product category
Off-label use of a manufactured medicine and use of a compounded preparation are different. The first involves a product used outside its approved labeling; the second involves a finished medicine without FDA approval. Neither phrase should be hidden behind a generic statement that the ingredients are familiar.
The prescription-reading guide helps identify the exact product. Ask about the route and how readily the exposure can be reduced or stopped if adverse effects occur.
Ask what monitoring changes
A useful plan explains when symptoms and laboratory results will be reviewed, how excessive exposure is avoided and what would lead to stopping. A laboratory target is not a substitute for a clinical outcome, and reference ranges should not be used to adjust a prescription yourself.
ACOG notes limitations in testosterone testing at female concentrations and cautions about compounded therapy evidence. It recommends considering preparations other than pellets because of limited safety information and the difficulty of removing them. Discuss those limitations before accepting a long-acting intervention.
Understand adverse effects and transfer precautions
Discuss acne, unwanted hair growth, scalp hair loss, voice changes and other androgenic effects. Some changes may not fully reverse. Ask what to report promptly and how the prescriber distinguishes a tolerability issue from excessive exposure.
For topical products, follow the specific instructions to prevent transfer to another person. Ask about pregnancy potential and contact with children or partners. Do not borrow a partner’s testosterone product or improvise a lower amount.
Compare provider claims against the actual plan
Midi describes a compounded testosterone program with state-dependent availability. Defy discusses testosterone in a broader hormone menu. Their marketing does not establish a universal benefit or a reason for every menopause patient to use it.
Before enrolling, request the medicine, cost of monitoring, follow-up schedule and stopping criteria. The care checklist keeps those details together. A clearly explained decision is more useful than a promise to optimize a number.
CHECK THE ORIGINAL
The source record
Provider pages document their own offers. Medical and regulatory sources provide treatment context. This is not a record of personal patient testing. All sources checked September 20, 2026.